Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$35.24 USD
-0.32 (-0.90%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $35.24 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
TNDM 35.24 -0.32(-0.90%)
Will TNDM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TNDM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TNDM
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues
TNDM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?
Tandem Diabetes (TNDM) Gains From Innovation Amid Competition
Why Is Tandem Diabetes Care (TNDM) Up 27.4% Since Last Earnings Report?
Other News for TNDM
Leerink upgrades Tandem Diabetes to Outperform on attractive risk/reward setup
Leerink gets more bullish on Tandem Diabetes, upgrades shares
What's Driving Tandem Diabetes Care Inc's Surprising 31% Stock Rally?
Tandem Diabetes price target raised by $3 at Stifel, here's why
Cracking The Code: Understanding Analyst Reviews For Tandem Diabetes Care